Among that, the levels of T cell infiltration, the polarization of tumor-associated macrophages (TAM) can be varied, thereby affecting the prognosis of patients differently, the expression of PD-1 and PD-L1 in TME, the mutational landscapes, and the drug responses of malignant cells can also be distinct in different patients, relating to different efficacies of immune checkpoint blockade (ICB) therapies (2–4). This evidence concerns the gene PDCD1 and neoplasm.